Nucleotide-based prodrugs

A nucleotide-based prodrug comprising a nucleotide component covalently bonded via a physiologically hydrolyzable junctional ester bond to a drug component;

• wherein said nucleotide-based prodrug is selected from a compound having the following formula:
• wherein X is independently selected from the group consisting of a drug with a hydroxyl group, a drug with a carboxyl group and H;
• R is independently selected from the group consisting of H, OH, F, OCH3 and NH2;
• N is a photocrosslinkable base;
• and
• n=1-150.

A method of preparing a nucleotide-based prodrug;

• wherein said nucleotide-based prodrug is selected from a compound having the following formula:
• wherein
• X is independently selected from the group consisting of a drug with a hydroxyl group, a drug with a carboxyl group and H;
• R is independently selected from the group consisting of H, OH, F, OCH3 and NH2;
• N is independently selected from the group consisting of any base of modification or analog thereof, or non-nucleoside drug selected from the group consisting of ceramide and analogs thereof, vitamin D and analogs thereof and retinoids;
• Z is selected from a lipid bilayer vesicle or a macromolecular support;
• and
• n=1-150,
• said method comprising covalently bonding a nucleotide component to a drug component via a physiologically hydrolyzable junctional ester bond.

A method of preparing a nucleotide-based prodrug;

• wherein said nucleotide-based prodrug is selected from a compound having the following formula:
• wherein X is independently selected from the group consisting of a drug with a hydroxyl group, a drug with a carboxyl group and H;
• R is independently selected from the group consisting of H, OH, F, OCH3 and NH2;
• N is a photocrosslinkable base;
• and
• n=1-150.